AgomAb Therapeutics N.V. American Depositary (AGMB) Fundamentals 2026 — Revenue Analysis | SniperIQ
AgomAb Therapeutics N.V. American Depositary (AGMB) is a BE-listed Healthcare company in Biotechnology with a market capitalization of $577M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AgomAb Therapeutics N.V. American Depositary's market cap?
AgomAb Therapeutics N.V. American Depositary (AGMB) has a market capitalization of approximately $577M, trading at
What is AgomAb Therapeutics N.V. American Depositary's P/E ratio?
AgomAb Therapeutics N.V. American Depositary's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AgomAb Therapeutics N.V. American Depositary?
AgomAb Therapeutics N.V. American Depositary runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does AgomAb Therapeutics N.V. American Depositary pay a dividend?
AgomAb Therapeutics N.V. American Depositary does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is AgomAb Therapeutics N.V. American Depositary financially healthy?
AgomAb Therapeutics N.V. American Depositary carries a debt-to-equity ratio of 0.01x and a current ratio of 6.52x, with a market beta of 1.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AgomAb Therapeutics N.V. American Depositary a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AgomAb Therapeutics N.V. American Depositary (AGMB) the key facts are: market cap $577M, 52-week range 8.75-17.82. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track AgomAb Therapeutics N.V. American Depositary's full fundamentals live
Get AgomAb Therapeutics N.V. American Depositary's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.